|
Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
|
Feb 2021
|
Blood Advances
|
myelodysplastic syndromes (MDS)
|
|
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol
|
Aug 2016
|
Ann Hematol
|
myelodysplastic syndromes (MDS)
|
|
Azacitidine in the management of patients with myelodysplastic syndromes.
|
Dec 2012
|
Ther Adv Hematol
|
myelodysplastic syndromes (MDS)
|
|
Autoimmunity and Inflammation in Myelodysplastic Syndromes
|
Jun 2016
|
Acta Haematol
|
myelodysplastic syndromes (MDS)
|
|
Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant?
|
Jan 2021
|
Leukemia
|
myelodysplastic syndromes (MDS)
|
|
Asymptomatic cerebral bleeds in patients with aplastic anemia.
|
Mar 2012
|
Ann Hematol
|
aplastic anemia
|
|
Asthma and risk of myelodysplastic syndromes: a population-based cohort study
|
Nov 2016
|
Br J Cancer
|
myelodysplastic syndromes (MDS)
|
|
Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia
|
Feb 2017
|
JAMA Oncol
|
acute myeloid leukemia (AML), myelodysplastic syndromes (MDS)
|
|
Association of Therapy for Autoimmune Disease With Myelodysplastic Syndromes and Acute Myeloid Leukemia
|
Feb 2017
|
JAMA Oncol
|
|
|
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents
|
Oct 2019
|
Leukemia & Lymphoma
|
myelodysplastic syndromes (MDS)
|
